Activation of β-adrenergic receptors increases the in vitro migration of malignant hepatocytes [0.03%]
β-肾上腺素能受体的激活可增加恶性肝细胞的体外迁移能力
Carly Lodewyks,Jose F Rodriguez,Jing Yan et al.
Carly Lodewyks et al.
Aim: Activation of adrenergic receptors (AR) has been reported to enhance the growth and invasion of various malignancies. The effects of AR agonists on malignant hepatocyte proliferation and migration have yet to be det...
Dexamethasone attenuates lipopolysaccharide-induced liver injury by downregulating glucocorticoid-induced tumor necrosis factor receptor ligand in Kupffer cells [0.03%]
糖皮质激素诱导的肿瘤坏死因子受体配体下调介导库普弗细胞脂多糖诱导的小鼠肝损伤中的地塞米松治疗效应
Si D Wei,Jin Z Li,Zuo J Liu et al.
Si D Wei et al.
Aim: Glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) plays pro-inflammatory roles in immune response. Thus, our aim was to assess if dexamethasone attenuates lipopolysaccharide (LPS)-induced liver in...
Toshihiko Mizuta
Toshihiko Mizuta
Liver stiffness measurement using transient elastography and hepatocellular carcinoma [0.03%]
瞬时弹性图测量肝硬度和肝细胞癌的关系
Haruhisa Nakao,Masashi Yoneda
Haruhisa Nakao
Liver fibrosis has been gaining noticeable attention because it may lead to end-stage liver cirrhosis and ultimately to hepatocellular carcinoma. Thus, a precise estimation of the degree of liver fibrosis is crucial for predicting prognosis...
Kazushi Sugimoto,Yoshiyuki Takei
Kazushi Sugimoto
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide and its incidence is increasing concomitantly with the increase in the prevalence of metabolic syndrome. Fatty liver encompasses a broad pa...
Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection [0.03%]
干扰素治疗对慢性病毒性肝炎患者肝癌进展的抗致癌作用
Soji Shimomura,Shuhei Nishiguchi
Soji Shimomura
Hepatocellular carcinoma (HCC) is mainly caused by a persistent infection due to the hepatitis B or hepatitis C virus. The number of HCC cases is increasing in Asian and African countries, as well as in European and American countries. Inte...
Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice [0.03%]
依折麦布对非酒精性脂肪肝病shionogi肥胖小鼠的治疗作用研究
Tomomitsu Matono,Masahiko Koda,Shiho Tokunaga et al.
Tomomitsu Matono et al.
Aim: An effective therapy for non-alcoholic steatohepatitis has yet to be defined. This study examined the therapeutic effects of ezetimibe, a lipid-lowering medication, on steatosis and hepatic fibrosis in fatty liver S...
Favorable factors for re-treatment with pegylated interferon α2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus [0.03%]
利巴韦林联合聚乙二醇化干扰素α2а对高病毒载量基因1型丙型肝炎患者的再治疗有益因素分析
Akihiro Tamori,Kiyohide Kioka,Osamu Kurai et al.
Akihiro Tamori et al.
Aim: Effect of re-treatment for pegylated interferon (PEG-IFN) plus ribavirin was not fully evaluated. We examined the effects of re-treatment with PEG-IFN plus ribavirin in patients with high viral loads of genotype 1 h...
Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy [0.03%]
慢性丙型肝炎（基因型2）患者中的肝脏脂肪变性与胰岛素抵抗和肝脏纤维化相关，并影响聚乙二醇干扰素和利巴韦林联合治疗中血清丙型肝炎病毒RNA累积阳转率
Yoshito Itoh,Takeshi Nishimura,Kanji Yamaguchi et al.
Yoshito Itoh et al.
Aim: Hepatic steatosis is one of the factors limiting the virological response to interferon-based antiviral therapy for chronic hepatitis C (CH-C) patients infected with genotype 1, while contradictory results have been...
Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation [0.03%]
利巴韦林联合低剂量聚乙二醇干扰素α-2b治疗基因1b型且高HCV RNA水平丙肝患者的持续应答预测指标：早期病毒学应答指标的价值评估研究
Hideyuki Tamai,Naoki Shingaki,Tatsuya Shiraki et al.
Hideyuki Tamai et al.
Aim: Continuation of pegylated interferon (PEG-IFN) plus ribavirin at the recommended dose is difficult in elderly patients and/or patients with cytopenia or complications. Whether the therapeutic efficacy of low-dose PE...